S. Lacy

发表

Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma

S. Chapel, L. Nguyen, B. Tran, 2019, Journal of clinical pharmacology.

A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types

M. Hutmacher, J. Nielsen, Bei Yang, 2018, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in medullary thyroid cancer patients receiving cabozantinib

N. Jumbe, D. R. Wada, D. Miles, 2016, Anti-cancer drugs.

Reductase-mediated metabolism of motexafin gadolinium (Xcytrin) in rat and human liver subcellular fractions and purified enzyme preparations.

D. Miles, S. Lacy, Shubhra Upadhyay, 2005, Journal of pharmaceutical sciences.

Cytochrome P-450- and glutathione-associated enzyme activities in freshly isolated enriched lung cell fractions from β-naphthoflavone-treated male F344 rats

J. Everitt, J. Mangum, S. Lacy, 1992 .

Evaluation of the effect of food and gastric pH on the single‐dose pharmacokinetics of cabozantinib in healthy adult subjects

J. Grenier, L. Nguyen, S. Lacy, 2015, Journal of clinical pharmacology.

Cabozantinib exposure–response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma

S. Chapel, L. Nguyen, B. Tran, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo

Z. H. Li, K. Kent, D. Mendel, 1994, Antimicrobial Agents and Chemotherapy.

Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys.

William A. Lee, P. Tellier, K. Cundy, 1998, Toxicological sciences : an official journal of the Society of Toxicology.

The cyclic congener of cidofovir has reduced nephrotoxicity in three species

J. Lindsey, E. Kern, S. Lacy, 1995 .

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

R. Roman, P. North, J. Williams, 2011, American journal of physiology. Renal physiology.

BIOCHEMICAL STUDIES ON ADENOVIRUS MULTIPLICATION. VII. HOMOLOGY BETWEEN DNA'S OF TUMORIGENIC AND NONTUMORIGENIC HUMAN ADENOVIRUSES.

M. Green, S. Lacy, 1964, Proceedings of the National Academy of Sciences of the United States of America.

Oral Administration of a Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071 Protects Mice and Ferrets against Influenza Infection

R. Sidwell, C. Sweet, J. Huffman, 1998, Antimicrobial Agents and Chemotherapy.

Adenovirus Multiplication: Genetic Relatedness of Tumorigenic Human Adenovirus Types 7, 12, and 18

S. Lacy, M. Green, 1965, Science.

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib

D. Ramies, R. Preston, T. Marbury, 2016, Journal of clinical pharmacology.

Pulmonary lesions induced by 3-methylindole and bovine respiratory syncytial virus in calves.

J. Atz, D. Slauson, W. Castleman, 1990, American Journal of Veterinary Research.

Metabolism of acrylonitrile to 2-cyanoethylene oxide in F-344 rat liver microsomes, lung microsomes, and lung cells.

S. Lacy, M. Turner, A. E. Roberts, 1989, Drug metabolism and disposition: the biological fate of chemicals.

Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

D. Miles, L. Nguyen, S. Lacy, 2015, Journal of clinical pharmacology.

Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma

M. Hutmacher, J. Nielsen, Bei Yang, 2018, Cancer Chemotherapy and Pharmacology.

Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib

D. Miles, L. Nguyen, S. Lacy, 2017, Clinical Pharmacokinetics.

Distribution of nickel and cobalt following dermal and systemic administration with in vitro and in vivo studies.

S. Brown, K. Merritt, S. Lacy, 1996, Journal of Biomedical Materials Research.

Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites

Dale Miles, Steven Lacy, Bih Hsu, 2015, Drug Metabolism and Disposition.

Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes

Y. Yaron, D. R. Wada, D. Miles, 2017, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults

E. Offman, L. Nguyen, S. Lacy, 2016, Anti-cancer drugs.

A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies

H. Wakelee, B. Sikic, A. Adjei, 2005 .

Pharmacokinetics of cabozantinib in Asian and non-Asian populations.

F. Benzaghou, S. Lacy, T. Nguyen, 2018, Annals of Oncology.

DMD063610 1190..1207

D. Miles, L. Nguyen, S. Lacy, 2015 .

Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis

N. Jumbe, D. Miles, L. Nguyen, 2015, Clinical Pharmacokinetics.

Evaluation of the effect of food and gastric pH on the single‐dose pharmacokinetics of cabozantinib in healthy adult subjects

J. Grenier, L. Nguyen, S. Lacy, 2015, Journal of clinical pharmacology.

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib

D. Ramies, R. Preston, T. Marbury, 2016, Journal of clinical pharmacology.